日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

皮下注射后，FcRn结合突变增强的Fc工程化治疗性单克隆抗体的人体药代动力学定量预测

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70482
Haraya, Kenta; Kuramochi, Taichi
单克隆抗体
FcRn
Human
发表日期：2026
文献求助 收藏

Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice

利用人FcRn转基因小鼠预测Fc工程化治疗性单克隆抗体的人体药代动力学

期刊:MAbs
影响因子:7.3
doi:10.1080/19420862.2025.2484443
Haraya, Kenta; Ichikawa, Takuya; Murao, Naoaki; Katada, Hitoshi; Kuramochi, Taichi
单克隆抗体
FcRn
发表日期：2025
文献求助 收藏

NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation

NXT007 通过独特的复合物形成，增强了 A 型血友病患者与艾美赛珠单抗共存时的体外凝血潜能。

期刊:Research and Practice in Thrombosis and Haemostasis
影响因子:3.4
doi:10.1016/j.rpth.2025.103236
Yamaguchi, Kazuki; Haraya, Kenta; Koga, Hikaru; Nishimura, Kei; Inaba, Keito; Muraoka, Masaru; Muto, Atsushi; Kitazawa, Takehisa
发表日期：2025
文献求助 收藏

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

超越抗体回收利用：Crovalimab 的分子设计使其能够每四周进行一次皮下注射，用于治疗 PNH

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms252111679
Sampei Zenjiro, Haraya Kenta, Gan Siok Wan, Muraoka Masaru, Hayasaka Akira, Fukuzawa Taku, Shida-Kawazoe Meiri, Tsuboi Yoshinori, Gotoh Akihiko, Obara Naoshi, Ueda Yasutaka
免疫/内分泌
发表日期：2024
文献求助 收藏

Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations

利用转化医学方法预测具有增强的FcRn结合突变的工程化治疗性单克隆抗体的人体药代动力学

期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-022-00566-2
Haraya, Kenta; Tachibana, Tatsuhiko
单克隆抗体
FcRn
Human
发表日期：2023
文献求助 收藏

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation

利用建模和仿真预测治疗性抗体转化药代动力学和药效学的最新进展

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph15050508
Haraya, Kenta; Tsutsui, Haruka; Komori, Yasunori; Tachibana, Tatsuhiko
发表日期：2022
文献求助 收藏

Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data

基于对临床数据的综合分析，仅利用皮下注射数据估算治疗性单克隆抗体在人体内的清除率和生物利用度

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-021-01023-z
Haraya, Kenta; Tachibana, Tatsuhiko
单克隆抗体
Human
发表日期：2021
文献求助 收藏

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

抗因子IXa/X双特异性抗体ACE910可预防获得性血友病A的长期灵长类动物模型中的关节出血。

期刊:Blood
影响因子:23.1
doi:10.1182/blood-2014-07-585737
Muto, Atsushi; Yoshihashi, Kazutaka; Takeda, Minako; Kitazawa, Takehisa; Soeda, Tetsuhiro; Igawa, Tomoyuki; Sampei, Zenjiro; Kuramochi, Taichi; Sakamoto, Akihisa; Haraya, Kenta; Adachi, Kenji; Kawabe, Yoshiki; Nogami, Keiji; Shima, Midori; Hattori, Kunihiro
发表日期：2014
文献求助 收藏